CN103402506A - 用于治疗糖尿病的组合 - Google Patents

用于治疗糖尿病的组合 Download PDF

Info

Publication number
CN103402506A
CN103402506A CN2012800085850A CN201280008585A CN103402506A CN 103402506 A CN103402506 A CN 103402506A CN 2012800085850 A CN2012800085850 A CN 2012800085850A CN 201280008585 A CN201280008585 A CN 201280008585A CN 103402506 A CN103402506 A CN 103402506A
Authority
CN
China
Prior art keywords
combination
metformin
diabetes
ascorbic acid
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800085850A
Other languages
English (en)
Chinese (zh)
Inventor
S·Y·列什科夫
N·S·维赫列娃
S·P·克列切托夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN103402506A publication Critical patent/CN103402506A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/742—Coffea, e.g. coffee
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2012800085850A 2011-06-02 2012-04-05 用于治疗糖尿病的组合 Pending CN103402506A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2011122374/15A RU2451506C1 (ru) 2011-06-02 2011-06-02 Комбинация для лечения сахарного диабета и его осложнений
RU2011122374 2011-06-02
PCT/RU2012/000254 WO2012166008A1 (en) 2011-06-02 2012-04-05 Combination for treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
CN103402506A true CN103402506A (zh) 2013-11-20

Family

ID=46231593

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800085850A Pending CN103402506A (zh) 2011-06-02 2012-04-05 用于治疗糖尿病的组合

Country Status (7)

Country Link
EP (1) EP2714022A1 (enExample)
JP (1) JP2014527506A (enExample)
KR (1) KR101567660B1 (enExample)
CN (1) CN103402506A (enExample)
EA (1) EA028394B1 (enExample)
RU (1) RU2451506C1 (enExample)
WO (1) WO2012166008A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105902761A (zh) * 2016-06-16 2016-08-31 河南中医学院 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2548731C2 (ru) * 2012-10-24 2015-04-20 Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" Средство и способ комплексной терапии больных сахарным диабетом
JP6440212B2 (ja) * 2013-05-24 2018-12-19 株式会社加齢・栄養研究所 メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
US10442610B2 (en) 2014-03-11 2019-10-15 Starbucks Corporation Pod-based restrictors and methods
FR3062795B1 (fr) * 2017-02-16 2019-06-07 Valbiotis Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal.
RU2687256C1 (ru) * 2018-03-26 2019-05-08 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией
EP3804705B1 (en) * 2018-06-07 2023-09-13 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468106A (zh) * 2000-08-01 2004-01-14 ����ե�ͻ���ʽ���� 糖类吸收抑制剂及其制备方法
US20060159773A1 (en) * 2005-01-20 2006-07-20 Stephen Holt Herbal compositions containing hoodia
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
CN101250106A (zh) * 2008-03-27 2008-08-27 北京市农林科学院 一种提取绿原酸的方法
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101851221A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种从落叶松中制备二氢槲皮素的方法
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004304A4 (en) * 1996-12-24 2002-10-16 Sumitomo Pharma COMPOSITION CONTAINING ASCORBIC ACID
ES2206868T3 (es) 1998-07-15 2004-05-16 Merck Sante Comprimidos que comprenden una combinacion de metformin glibenclamida.
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
RU2280447C2 (ru) 1999-09-17 2006-07-27 Новартис Аг Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом
JP4719372B2 (ja) * 2000-06-21 2011-07-06 花王株式会社 Ｐｐａｒ依存的遺伝子転写活性化剤
JP2003300904A (ja) * 2002-04-05 2003-10-21 National Cardiovascular Center 循環器系障害の進展を抑制する医薬組成物
JP2007505854A (ja) * 2003-09-23 2007-03-15 ディーエスエム アイピー アセッツ ビー．ブイ． 糖尿病の治療および予防用組成物
EP1670485A4 (en) * 2003-10-10 2009-03-11 Resverlogix Corp TREATMENT OF ILLNESSES ASSOCIATED WITH THE EGR-1 AMPLIFIER ELEMENT
RU2284829C2 (ru) * 2004-12-16 2006-10-10 Пятигорская государственная фармацевтическая академия Антидиабетический сбор
TW200740460A (en) * 2005-07-12 2007-11-01 Sankyo Co Pharmaceutical composition containing PPAR γ agonist
JP5246833B2 (ja) * 2005-12-16 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
TW200903710A (en) 2007-07-11 2009-01-16 Promos Technologies Inc Manufacturing method for shallow trench isolation
JP5054594B2 (ja) * 2008-03-31 2012-10-24 花王株式会社 脂質代謝改善剤
RU2378003C1 (ru) 2008-06-06 2010-01-10 Сергей Юрьевич Лешков Фармацевтическая композиция на основе экстракта зеленой ягоды кофе, способ получения и применения
EP2348868A4 (en) 2008-10-22 2013-06-12 Metaproteomics Llc NEW MITOCHONDRIAL DECOMPOSITION PROCESSES AND COMPOSITIONS FOR IMPROVED THERMOGENESIS IN FAT CELLS
WO2010089874A1 (ja) * 2009-02-05 2010-08-12 フジッコ株式会社 ＰＰＡＲ－γ発現増強剤、アディポネクチン産生促進剤、ＵＣＰ活性剤およびそれらを用いた医薬品・飲食品
EP2418965B1 (en) * 2009-04-17 2016-06-29 DSM IP Assets B.V. Hydroxytyrosol combinations for enhancing mitochondrial function and energy production.
JP2011063557A (ja) * 2009-09-18 2011-03-31 Lion Corp Ｐｐａｒ活性化剤
ES2356536B1 (es) * 2009-09-23 2012-02-13 Probelte Pharma, Sa Una composición de uso como prebiótico que contiene un extracto de granada y un alimento que incluye dicha composición.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1468106A (zh) * 2000-08-01 2004-01-14 ����ե�ͻ���ʽ���� 糖类吸收抑制剂及其制备方法
US20060159773A1 (en) * 2005-01-20 2006-07-20 Stephen Holt Herbal compositions containing hoodia
CN101176786A (zh) * 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
US20090175973A1 (en) * 2007-09-05 2009-07-09 Nina Vikhrieva Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders
CN101250106A (zh) * 2008-03-27 2008-08-27 北京市农林科学院 一种提取绿原酸的方法
WO2010134085A1 (en) * 2009-05-20 2010-11-25 Institute Of Life Sciences Pharmaceutical co-crystals of quercetin
CN101851221A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种从落叶松中制备二氢槲皮素的方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
SEFA CELIK等: "Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocininduced diabetic rats", 《PHARMACOLOGICAL RESEARCH》, vol. 60, no. 4, 31 October 2009 (2009-10-31), pages 270 - 276 *
刘勤知: "糖尿病不能光治高血糖", 《家庭医学》, no. 7, 31 July 2002 (2002-07-31), pages 55 *
夏涛等: "类黄酮及茶儿茶素生物合成途径及其调控研究进展", 《中国农业科学》, vol. 42, no. 8, 30 April 2009 (2009-04-30), pages 2899 - 2908 *
王增: "辣椒可治糖尿病", 《健身科学》, no. 11, 30 November 2002 (2002-11-30), pages 39 *
石磊: "姜黄素对2型糖尿病大鼠血糖的影响", 《河北医学》, vol. 14, no. 10, 31 October 2008 (2008-10-31), pages 1195 - 1197 *
舒毅等: "槲皮素的药理学研究进展", 《华西药学杂志》, vol. 23, no. 6, 31 December 2008 (2008-12-31), pages 689 - 691 *
邢琳等: "《急诊医学》", 31 August 2005, 黑龙江教育出版社, article "糖尿病性乳酸酸中毒", pages: 183 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105902761A (zh) * 2016-06-16 2016-08-31 河南中医学院 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用

Also Published As

Publication number Publication date
EA028394B1 (ru) 2017-11-30
EA201301308A1 (ru) 2014-03-31
JP2014527506A (ja) 2014-10-16
KR101567660B1 (ko) 2015-11-10
RU2451506C1 (ru) 2012-05-27
EP2714022A1 (en) 2014-04-09
KR20140008452A (ko) 2014-01-21
WO2012166008A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
CN103402506A (zh) 用于治疗糖尿病的组合
Gökçay Canpolat et al. Glucose lowering treatment modalities of type 2 diabetes mellitus
CN107157999A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
JP6412241B2 (ja) 肝機能改善法
CN102727894A (zh) 一种治疗糖尿病及其并发症的药物组合物及其应用
CN104557944B (zh) 一种降糖药物及其制备方法
Nathan et al. SGLT-2 inhibitors: a novel mechanism in targeting glycemic control in type 2 diabetes mellitus
JP5117230B2 (ja) ２型糖尿病治療用の併用医薬
CN104582701A (zh) 减轻体重的方法
CA3104916C (en) Pharmaceutical composition for preventing diabetes and use thereof
CN113559088A (zh) 一种含二甲双胍和西格列汀的复方降糖药物制剂
JP2009062348A (ja) ケナフ類（ケナフ、ローゼル）の種子成分による血糖値低下作用及び血糖値上昇抑制作用
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
CN110575447A (zh) 一种用于防治糖尿病的药物组合物及其用途
US20200268820A1 (en) Pharmaceutical composition and uses thereof
CN113491688A (zh) 一种控制血糖波动的药物组合物
AU2013202988B2 (en) Method of improving liver function
CN105343055A (zh) 一种含二甲双胍和五味子乙素的治疗糖尿病药物组合物
CN101756980A (zh) 一种二甲双胍/米格列醇降糖口服制剂组合物及其制备
JP2007091641A (ja) ２型糖尿病治療用の併用医薬
MX2012014757A (es) Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso.
HK1194307B (en) Lixisenatide and metformin for treatment of diabetes type 2

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131120